- Total Pro Portfolios with CVD:
- Target Small Capitalization Value TASVX
- Baron Asset - BARAX
- show more
- Total Do-It-Yourself Portfolios with CVD:
- Soomodh Abraham Portfolio 1
- admportfolioforQ2007
- mph1
- KKB Portfolio 1
- Karen M Portfolio 1
- Ross Parrish Portfolio 1
- TMac Portfolio 2
- Mike Pale Portfolio 1
- disweij Portfolio 1
- Making Money Portfolio
- SUPRATRADE THE FURIES
- REAP Club
- bbradshaw Portfolio 1
- 1.1
- HungryJoe Watch1
- farshid Portfolio 1
- Glamslam's Dartboard
- Huckleberry Portfolio 1
- SUPRATRADE "BUY IT ALL TODAY" 0908071816(09.august)
- Surviving Stocks after Market Correction (above 50 day moving average): August 15, 2007
- snake427 Portfolio 1
- OM's
- genomiks BIOMED
- BENITRANS ER(SUPRATRADE)
- lwahl Portfolio 1
- boldgolfer
- MCM08
- custom1
- ginny
- JMB 2008 Picks
- 10 Top-Rated Stocks IBD
- Buy??
- joezag Portfolio 1
- ultimate super technical plus fundamental power portfolio pro
- Barron's Research Reports 10-25-2008
- show more
- 70
- wrjjca
- Ray C's Portfolio
- Diversified Blend Portfolio
- Blun01
- BOB GLAZER Portfolio 1
- Interests
- C-TOWE
- btwist Portfolio 1
- JBX Portfolio 1
- reysr Portfolio 1
- Isaac4 Portfolio 1
- irishtickler Portfolio 1
- nalivia
- olympicwinebrokers Portfolio 1
- penn
- mdunle3199 Screen Program
- jcmcf2 Portfolio 1
- SOON 2 BUY
- MJC1
- Great 5 Year Charts, Continued.
- Trend Watch
- LongTermDiverse
- Abednego I
- Jill Portfolio 1
- Barron's Summary 11-10-2007
- Covered Calls for this month (see description)
- PART 1 JPMorgan 26th Annual Healthcare Conf 1/7/08..1st Day Reporting Companies..Nymph Take
- PAU
- KJMARINO's picks
- Cramer's Outsourcing R&D Stock Plays
- 4retire
- Croffoot
- The Ten Year Fund
- Fast Money's Bear Market Playbook
- MMB
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:barrons3 |
Date:10 25 08 |
Buy -- Price 69 on Oct. 22 |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:10 15 08 |
Terranova said CVD is a best of breed company with limited exposure to slowing economy. He said CVD has a business model geared toward reducing costs within the healthcare space, solid growth, strong balance sheet and Big Pharma is outsourcing R&D to reduce costs. |
|
Not yet rated
Rate now:
|
|
By:kirk48 |
Date:02 28 08 |
been good so far |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Covance (CVD) was upgraded to Buy rating from Neutral at UBS. Price target and FY 2008 eps estimates hold at $98 and $2.97, respectively. |
|
Not yet rated
Rate now:
|
|
By:gvphubli |
Date:01 28 08 |
Earnings Stability Rating: 3. Clinical trial provider’s earnings growth rate is expected to hold firm in 2008. Five-year earnings growth rate: 23%. |
|
Not yet rated
Rate now:
|
|
By:Stepford |
Date:01 19 08 |
Clinical trials company - organizes them and compiles results data. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:01 17 08 |
Cramer's favorite in this space is Covance (CVD). Covance, Cramer said, handles early and late stage testing and has a solid customer base. The company also has an immaculate balance sheet, according to Cramer. Covance has $250 million in cash, no debt and $300 million in expected free cash flow over the next two years. Cramer sees the potential for Covance to trade at 37 times this year's earnings, which translates to a target price of $115, or a 33% upside. Despite being just $1 off its 52-week high, Cramer said Covance "must be bought on any weakness." |
|
Not yet rated
Rate now:
|
|
By:KJMarino |
Date:01 16 08 |
CRO both stages |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:11 10 07 |
"With an approaching U.S. presidential election in which health care will be a major issue, the drug makers are clearly in the political cross-hairs. That can only accelerate the flow of new drug testing to the CROs, making Covance and PPD good long-term bets." |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Covance (CVD) was downgraded from Outperform to Peer Perform, Bear Stearns said. $84 price target. Valuation call, as the stock is up 30% since the end of April. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:tgramful |
Date:12 05 08 |
never performed, and they imported sick monkeys into the Texas |
|
Not yet rated
Rate now:
|
|



